Azelby Robert 4

What Happened
Robert Azelby, a director of Tango Therapeutics (TNGX), received equity awards on June 19, 2026. The filing shows an award of 5,740 restricted stock units (RSUs) and a derivative award of 35,910 shares (an option-like derivative), each recorded at $0.00 (grant/award). These are grants (transaction code A) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-19; reported on Form 4 filed 2026-06-23 (timely filed).
• Price: $0.00 for both awards (standard for grants/RSUs/options at grant).
• Award amounts: 5,740 RSUs + 35,910-share derivative award (total 41,650 share-equivalents granted).
• Vesting/terms noted in footnotes:
  • F1 (RSUs): the 5,740 RSUs convert to one share each and vest in three substantially equal annual installments, subject to continued service.
  • F2 (option/derivative): the derivative award vests in 36 substantially equal monthly installments over three years, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: Filed 6/23/2026 for a 6/19/2026 grant — within the standard two-business-day reporting window.

Context
These entries reflect equity compensation (awards/vesting schedules), not purchases or sales. RSU grants and option awards give the recipient a future right to shares if vesting conditions are met; they do not by themselves indicate buying or selling activity or immediate cash flows. Such grants are common for executives/directors as part of compensation packages.